Phase 3CompletedAge-related condition
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer (PSMAfore)
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
- Sponsor
- Novartis Pharmaceuticals (Industry)
- Enrollment
- 469 enrolled
- Conditions
- Prostatic Neoplasms
- Interventions
- 177Lu-PSMA-617; 68Ga-PSMA-11; ARDT
- Ages
- adults, older adults
- Registry
- NCT04689828, CTIS2023-507772-50-00
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to determine whether 177Lu-PSMA-617 improves the Radiographic progression-free survival (rPFS) or Overall Survival (OS) compared to a change in Androgen receptor-directed therapy (ARDT) in metastatic castrate resistant prostate cancer (mCRPC) participants that were previously treated with an alternate ARDT and not exposed to a taxane-containing regimen in the CRPC or mHSPC settings. 469 participants were randomized (235 in the 177Lu-PSMA-617 group and 234 in the ARDT group.
Primary outcomes
- Radiographic Progression Free Survival (rPFS)
History
Last registry update
Study completion
Results first posted
Primary completion
Started
Registered